Institut Pasteur

Institut National De La Sante Et De La Recherche Medicale

Other

Centre National De La Recherche Scientifique

UniversitÉ Paris Descartes

Assistance Publique-hopitaux De Paris

Iti Scotland Limited

Universite Paris Cité

Fondation Imagine

UniversitÉ Libre De Bruxelles

Centre National De La Recherche Scientifique-cnrs

Rijksuniversiteit Groningen

Inserm (institut National De La Sante Et De La Recherche Medicale)

Inserm

Philippe J Sansonetti

Armelle Phalipon

Laurence Mulard

Farida Nato

Annick Fontaine

Claude Parsot

Françoise Baleux

Julien Boutet

Yves-Marie Coic

Ivo Boneca

Catherine Boileau

Brigitte Demers

Benoit Marteyn

Frédéric Belot

Cyrille Grandjean

Helene D'Hauteville

Stephen Girardin

Dana Philpott

Catherine Guerreiro

Frederic Belot

David Bikard

Pierre Chassagne

Francois Traincard

Gerard Eberl

Franco Felici

Jean Pierre Kraehenbuhl

Pamela Schnupf

Nadine Cerf Bensussan

Valerie Gaboriau-Routhiau

Riccardo Cortese

Jost Enninga

Musa Mhlanga

Claude Rene Raoul Parsot

John Roy Rohde

Kim Dong Wook

Ulf Nehrbass

Laurence Arbibe

François Traincard

Gérard Eberl

Valérie Gaboriau-Routhiau

Anne Botteaux

Musa Sani

Egbert J Boekema

Adbelmounaaïm Allaoui

The present invention relates to an in vitro method of culturing a segmented filamentous bacterium strain, comprising co-culturing said segmented filamentous bacterium strain with a eukaryotic host cell, wherein the culture is performed at an Olevel inferior to 5% in a rich tissue culture liquid medium containing bacterial medium components including iron. The present invention also relates to methods for genetically modifying a segmented filamentous bacterium strain comprising a step a culturing the strain in vitro.

Method of culturing segmented filamentous bacteria in vitro

The present invention relates to a conjugate comprising an oligo- or polysaccharide selected from the group consisting of: (X)-{BCDA}-(Y)(X)-{CDAB}-(Y)(X)-{DABC}-(Y)(X)-{ABCD}n-(Y)wherein A, B, C, D, X and Y, x, y and n are as defined in claim, said oligo- or polysaccharide being bound to a carrier.

Glycoconjugates and their use as potential vaccines against infection by

The invention relates to polypeptides, defined through a consensus sequence, having a length from 10 to 80 amino-acid residues, and whose polypeptidic sequence comprises or consists of the consensus sequence P1(X)P3(X)P5(X)P6(X)P7 (SEQ ID NO: 1), presenting specific patterns. The polypeptides of the invention target glycosylated Muc2 proteins. The invention also relates to methods of synthesis of such polypeptides, to their nucleic acids and uses thereof. The polypeptidic sequence of the polypeptides of the invention can be part of the N-terminal sequence of a mucus-binding (MUB) domain, especially a mucus-binding (MUB) domain of several species. The invention also relates to chimeric molecule(s) comprising such polypeptides, which are labelled, and vectors, especially plasmids and population of cells or composition comprising polypeptides of the invention. Synthesis methods encompass biotechnological or chemical production. Polypeptides of the invention can be used in staining experiments, as a probe or marker for staining Muc2 protein(s) contained in mucus layer(s), to detect in vitro mucus production or mucus composition in human colon or monitoring any one of the following disease conditions: neoplasic disease(s), including mucinous carcinoma(s), gastric cancer(s) or colorectal cancer(s), especially colon cancer(s), cystic fibrosis, intestine inflammatory disease(s) such as inflammatory bowel disease (IBD) and ulcerative colitis. The invention also relates to a method for manufacturing a medicament. In a particular embodiment, use of polypeptides of the invention can be made for marking neutrophiles.

Polypeptides targeting glycosylated MUC2 proteins, methods of synthesis, their nucleic acids and uses thereof

The present invention relates to compounds derived from sugars which reproduce the epitopes ofserotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing ainfection using one or more oligosaccharides or polysaccharides or conjugates thereof.

[object Object]

The invention relates to a double-stranded polynucleotide comprising on its positive strand considered from its 5' end to its 3&#x2032; end, (i) a promoter of a gene of interest or several promoters of various genes of interest selected among genes which are endogenous to a determined cell, and, (ii) one or several barcode(s) wherein each barcode contains at least one barcode unit formed of at least one, especially of multiple, recognition binding sites each binding site being composed of a nucleotide sequence, and wherein each of said barcode(s) is under the control of at least one of said promoter(s) for transcription. It further concerns use of said polynucleotide to monitor gene expression patterns in living cells, especially in single cells, with a rapid and high spatio-temporal resolution.

Single cell based reporter assay to monitor gene expression patterns with high spatio-temporal resolution

A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by

The ospF gene ofencodes a phosphatase, which is a member of a new class of phosphatases. The OspF phosphatase inhibits the activity of several proteins either by direct protein modification or transcription downregulation. These proteins include MAP kinase, IL-8, CCL20, IL-12, AP1, CREB, RPA p32, and BCL2 related proteins. Methods for treating diseases using OspF phosphatase, methods for identifying agents that modulate OspF phosphatase's activity, methods for identifying agents that mimic OspF phosphatase's activity, and immunogenic compositions comprising OspF phosphatase are provided. A strain ofcontaining an inactivated ospF gene is also provided.

Targeting the histone code as a bacterial strategy for selectively modulating gene expression

Members of the IpaH superfamily constitute a novel class of E3 ubiquitin ligases which are useful for engineering products which modulate trafficking and destruction of target proteins inside a cell and useful targets for identifying new antimicrobial molecules which modulate, especially inhibit, E3 ligases.

Targeted ubiquitination of proteins and screening methods using a new class of ubiquitin ligase proteins

A method for modifying a wild strain of an entero-invasiveto produce a modified strain ofthat can be used for making a vaccine against the wild strain of. The genome of the wild strain ofis transformed so that it cannot substantially invade cells of a human host and cannot spread substantially within infected cells and from infected to uninfected cells of the host and cannot produce toxins which will kill substantial numbers of the host's infected, as well as uninfected, cells. A first gene of the wild strain of, coding for a protein necessary for theto invade cells of the host, and a second gene, coding for a protein necessary for theto spread within infected cells and between the infected and uninfected cells of the host, are mutagenized.

A method for modulating Nod1 activity wherein said method comprises the steps of providing cells expressing a functional Nod1; and bringing said cells into contact with a molecule related to compositions comprising a molecule related to MTP and use of a molecule related to MTP for modulating inflammation and/or apoptosis.

Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof

A method for modulating Nod 1 activity wherein said method comprises the steps of providing cells expressing a functional Nod 1; and bringing said cells into contact with a molecule related to compositions comprising a molecule related to MTP and use of a molecule related to MTP for modulating inflammation and/or apoptosis

Growing community of inventors

Paris, France

Philippe J Sansonetti